Baxter to end Alzheimer's trial of Gammagard

05/8/2013 | Yahoo

Baxter International said it is stopping Phase III trials of Gammagard as an Alzheimer's disease drug after it failed to ameliorate mental decline and functional ability in patients. Gammagard, also known as intravenous immunoglobulin, was the only Alzheimer's treatment in Phase III development. The firm said it will re-evaluate its Alzheimer's program and make a decision after analyzing the trial's full results.

View Full Article in:

Yahoo

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Trials Agreements Specialist (209955)
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
Rockville, MD
Catheter Engineer Manager
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Senior Manager, Compliance
Stryker
Fremont, CA
Director, Office of Device Evaluation
FDA, Center for Devices and Radiological Health
Silver Spring, MD